150 related articles for article (PubMed ID: 34433662)
1. Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
Mercer-Smith AR; Jiang W; Bago JR; Valdivia A; Thang M; Woodell AS; Montgomery SA; Sheets KT; Anders CK; Hingtgen SD
Mol Cancer Ther; 2021 Nov; 20(11):2291-2301. PubMed ID: 34433662
[TBL] [Abstract][Full Text] [Related]
2. Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers.
Jiang W; Yang Y; Mercer-Smith AR; Valdivia A; Bago JR; Woodell AS; Buckley AA; Marand MH; Qian L; Anders CK; Hingtgen SD
Sci Adv; 2021 Jun; 7(24):. PubMed ID: 34108203
[TBL] [Abstract][Full Text] [Related]
3. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
4. Next-generation Tumor-homing Induced Neural Stem Cells as an Adjuvant to Radiation for the Treatment of Metastatic Lung Cancer.
Mercer-Smith AR; Buckley A; Valdivia A; Jiang W; Thang M; Bell N; Kumar RJ; Bomba HN; Woodell AS; Luo J; Floyd SR; Hingtgen SD
Stem Cell Rev Rep; 2022 Oct; 18(7):2474-2493. PubMed ID: 35441348
[TBL] [Abstract][Full Text] [Related]
5. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
7. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model.
Han X; Zhao N; Zhu W; Wang J; Liu B; Teng Y
Cell Immunol; 2021 Oct; 368():104423. PubMed ID: 34399171
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
10. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
[TBL] [Abstract][Full Text] [Related]
12. Targeting PP2A inhibits the growth of triple-negative breast cancer cells.
Uddin MH; Pimentel JM; Chatterjee M; Allen JE; Zhuang Z; Wu GS
Cell Cycle; 2020 Mar; 19(5):592-600. PubMed ID: 32011210
[TBL] [Abstract][Full Text] [Related]
13. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
15. Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer.
Ghosh S; Lalani R; Maiti K; Banerjee S; Bhatt H; Bobde YS; Patel V; Biswas S; Bhowmick S; Misra A
Nanomedicine; 2021 Jan; 31():102320. PubMed ID: 33075540
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches.
Ghosh S; Javia A; Shetty S; Bardoliwala D; Maiti K; Banerjee S; Khopade A; Misra A; Sawant K; Bhowmick S
J Control Release; 2021 Sep; 337():27-58. PubMed ID: 34273417
[TBL] [Abstract][Full Text] [Related]
17. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer.
Kamalabadi-Farahani M; Vasei M; Ahmadbeigi N; Ebrahimi-Barough S; Soleimani M; Roozafzoon R
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1011-S1021. PubMed ID: 30580635
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
